Navigation Links
ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
Date:4/30/2008

HALIFAX, April 30 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, unveiled today its DepoVax(TM) platform, a novel depot vaccine delivery system used to increase the efficacy and strength of vaccines. IVT has filed additional patents to protect the DepoVax(TM) concept.

"The results from our preclinical studies demonstrate that DepoVax(TM) is highly effective with a single dose," remarked Marc Mansour, vice president of research and development at IVT. "DepoVax(TM) is superior to conventional vaccine formulations in its ability to raise strong cellular and humoral immune responses to a variety of antigens, a hallmark of IVT's vaccine formulations."

DepoVax(TM) has been tested in pandemic influenza and therapeutic cancer models. The research shows DepoVax(TM)-vaccines deliver effective, long lasting results with only one dose.

DepoVax(TM) vaccines are readily amenable to commercialization. They can be manufactured in large batches, and are well suited for large scale distribution and long term storage. DepoVax(TM) vaccines are packaged and stored in a dry form, ensuring the stability of antigens which can otherwise be unstable in aqueous formulations. DepoVax(TM) vaccines are also easy to administer by health care practitioners, an important consideration for immunization programs targeting infectious diseases in a population.

"Our patented technology offers a dramatic boost to the effectiveness of existing vaccines," said Randal Chase, president and CEO of IVT. "An effective and easy-to-administer DepoVax(TM) vaccine would be a valuable tool for health authorities dealing with a pandemic and we are planning to take this into the clinic as soon as possible."

About IVT

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
2. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
3. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
4. Sticky nanotubes hold key to future technologies
5. Adoption of Spinal Nonfusion Technologies Doubled in One Year
6. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
7. VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales
8. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
9. Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Mass. , March 22, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... RXi,s Chief Business Officer, will present at the ... forum will provide a platform to present to ... institutes, leading pharmaceutical and biotech companies as well ...
(Date:3/20/2017)... (PRWEB) , ... March 20, 2017 , ... SSCI and ... at the INTERPHEX 2017 ! Sponsored by the Parenteral Drug Association (PDA), ... 23. With over 12,000 industry professionals in attendance and more than 625 exhibitors, the ...
(Date:3/20/2017)... ... March 20, 2017 , ... HOLLOWAY ... companies, recently announced it will debut a brand new pressure vessel, the intelliVesselâ„¢, ... is controlled by a touch screen panel and features other revolutionary operations that ...
(Date:3/20/2017)... , ... March 20, 2017 , ... ... and laborious sample preparation methods in order to reduce the impact on instrumentation. ... of the area of elemental analysis. , This presentation will discuss the ...
Breaking Biology Technology:
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
Breaking Biology News(10 mins):